News (Updated May 21, 2006)

[Home]  [
Previous news]


San Francisco Makes HIV Tests Easier

By PAUL ELIAS, AP Biotechnology WriterWed May 17, 9:45 PM ET

City-run medical clinics will no longer require written consent and counseling sessions before testing people for HIV in a bid to increase the number of people screened for the virus, officials said Wednesday.

The city, at the forefront of the AIDS fight, becomes the first known entity in the U.S. to formally loosen consent and counseling requirements. The new policy was implemented Tuesday in the city clinics and two hospitals that test patients. Last year, 240 people tested positive out of the 6,000 tested in San Francisco.

The federal Centers for Disease Control and Prevention is contemplating making similar recommendations. The aim is to expand testing to find as many as 250,000 of the 1 million Americans with HIV who don't know they are infected and are most responsible for the spread of the virus.

San Francisco doctors will now be required to get only verbal patient permission for testing, lessening paperwork and burdensome bureaucracy.

"We hope others follow this common sense approach," said Dr. Jeffrey Klausner, director of the city's sexually transmitted disease prevention.

Many AIDS activists and other critics, however, fear the changes could lead to patient privacy abuses. Also, the lack of counseling might mean more people who test positive would fail to seek treatment.

"Unfortunately, HIV follows women of color and HIV follows poverty," said Diana Bruce of the Washington-based AIDS Alliance for Children, Youth & Families. "This population needs testing that is culturally competent, that builds their trust," and of which they have been informed in writing.

Dana Van Gorder of the San Francisco AIDS Foundation supports streamlining the testing process.

The city's General Hospital "has provided model care for HIV throughout the epidemic and I trust them to making good decisions about these changes," Van Gorder said in an e-mail.

RESEARCH TRIANGLE PARK, N.C. (AP) -- Drug makers GlaxoSmithKline PLC and Vertex Pharmaceuticals Inc. said Tuesday that early results of a clinical study show their HIV treatment Lexiva is comparable to the Kaletra anti-HIV drug combination sold by Abbott Laboratories Inc.

 

Glaxo-Vertex Study Tests Anti-HIV Drugs

Tuesday May 16, 10:21 am ET

In the 887-person study, patients were given twice a day either 700 milligrams of Lexiva along with 100 milligrams of ritonavir -- the active ingredient in Abbott's anti-AIDS drug Norvir -- or 400 milligrams of Kaletra with 100 milligrams of ritonavir.

Kaletra is a combination of ritonavir and another AIDS fighter called lopinavir.

Patients in both groups were also given 600 milligrams of abacavir and 300 milligrams of lamivudine, the active ingredients in GlaxoSmithKline's HIV drugs Ziagen and Epivir, respectively, once a day.

The study showed that 73 percent of patients in the Lexiva group showed suppression of HIV replication, compared with 71 percent in the Kaletra group after 48 weeks of treatment.

GlaxoSmithKline and Vertex said the comparisons were made because Kaletra is the preferred HIV protease inhibitor, which suppresses the HIV virus, in treatment guidelines developed by the Department of Health and Human Services and the International AIDS Society.

American depositary shares of GlaxoSmithKline rose $1.01 to $58.09 and Abbott shares were up 41 cents to $42.71 in early morning trading on the New York Stock Exchange. Shares of Vertex fell 20 cents to $33.01 on the Nasdaq.


[Home]  [Previous news]